Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 symbols : EBS save search
Emergent BioSolutions Announces Publication of CHIKV VLP Phase 2 Safety and Immunogenicity Data in The Lancet Infectious Diseases
Published: 2022-06-21 (Crawled : 11:00) - globenewswire.com
EBS | $2.04 9.68% 0.49% 930K
|
Health Technology
|
| O: 5.29%
H: 0.0%
C: 0.0%
lancet publication chikungunya disease phase 2
Emergent BioSolutions Initiates Phase 1 Study Evaluating Potential Intranasal Treatment for Cyanide Poisoning
Published: 2022-03-11 (Crawled : 12:00) - globenewswire.com
EBS | $2.04 9.68% 0.49% 930K
|
Health Technology
|
| O: -5.51%
H: 0.0%
C: 0.0%
treatment solutions phase 1 potential merge phase 2 phase 3
Emergent BioSolutions Announces Initiation of Phase 1 Study Evaluating Its Universal Influenza Vaccine Candidate
Published: 2021-12-16 (Crawled : 13:30) - biospace.com/
EBS | $2.04 9.68% 0.49% 930K
|
Health Technology
|
| O: 3.55%
H: 2.32%
C: 0.54%
phase 1 vaccine influenza merge phase 2 phase 3
Emergent BioSolutions Announces Positive Two-Year Persistence Data From Phase 2 Study Evaluating CHIKV VLP, the Company’s Chikungunya Virus Virus-Like Particle Vaccine Candidate
Published: 2021-05-26 (Crawled : 11:00) - globenewswire.com
EBS | $2.04 9.68% 0.49% 930K
|
Health Technology
|
| O: 0.44%
H: 1.34%
C: 1.04%
phase 2 positive vaccine merge chikungunya
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.